{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:26:05Z","timestamp":1783700765610,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Epidemiol Glob Health"],"DOI":"10.1007\/s44197-026-00518-x","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:37:20Z","timestamp":1771947440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Travel-Related Challenges of Chikungunya Virus and Vaccination Options"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-007X","authenticated-orcid":false,"given":"Mazin","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-9322","authenticated-orcid":false,"given":"Mohamad-Hani","family":"Temsah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5752-2235","authenticated-orcid":false,"given":"Jaffar A.","family":"Al-Tawfiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5099-0714","authenticated-orcid":false,"given":"Ziad A.","family":"Memish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"4","key":"518_CR1","doi-asserted-by":"publisher","first-page":"e0249166","DOI":"10.1371\/journal.pone.0249166","volume":"16","author":"F Ferreira","year":"2021","unstructured":"Ferreira F, da Silva ASV, Recht J, Guaraldo L, Moreira MEL, de Siqueira AM, et al. Vertical transmission of Chikungunya virus: A systematic review. PLoS ONE. 2021;16(4):e0249166. https:\/\/doi.org\/10.1371\/journal.pone.0249166.","journal-title":"PLoS ONE"},{"issue":"1","key":"518_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/0035-9203(55)90080-8","volume":"49","author":"MC Robinson","year":"1955","unstructured":"Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952\u20131953. Trans R Soc Trop Med Hyg. 1955;49(1):28\u201332.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"518_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.meegid.2008.09.004","volume":"9","author":"SS Cherian","year":"2009","unstructured":"Cherian SS, Walimbe AM, Jadhav SM, Gandhe SS, Hundekar SL, Mishra AC, et al. Evolutionary rates and timescale comparison of Chikungunya viruses inferred from the whole genome\/E1 gene with special reference to the 2005-07 outbreak in the Indian subcontinent. Infect Genet Evol. 2009;9(1):16\u201323. https:\/\/doi.org\/10.1016\/j.meegid.2008.09.004.","journal-title":"Infect Genet Evol"},{"key":"518_CR4","doi-asserted-by":"publisher","unstructured":"Roth A, Hoy D, Horwood PF, Ropa B, Hancock T, Guillaumot L, et al. Preparedness for threat of chikungunya in the pacific. Emerg Infect Dis. 2014;20(8). https:\/\/doi.org\/10.3201\/eid2008.130696.","DOI":"10.3201\/eid2008.130696"},{"key":"518_CR5","doi-asserted-by":"publisher","unstructured":"Javelle E, Florescu SA, Asgeirsson H, Jmor S, Eperon G, Leshem E, et al. Increased risk of chikungunya infection in travellers to Thailand during ongoing outbreak in tourist areas: cases imported to Europe and the Middle East, early 2019. Euro Surveill. 2019;24(10). https:\/\/doi.org\/10.2807\/1560-7917.es.2019.24.10.1900146.","DOI":"10.2807\/1560-7917.es.2019.24.10.1900146"},{"issue":"Pt 2","key":"518_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1099\/0022-1317-81-2-471","volume":"81","author":"AM Powers","year":"2000","unstructured":"Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of Chikungunya and O\u2019nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol. 2000;81(Pt 2):471\u20139. https:\/\/doi.org\/10.1099\/0022-1317-81-2-471.","journal-title":"J Gen Virol"},{"issue":"2","key":"518_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1586\/14760584.2015.965690","volume":"14","author":"K Ljungberg","year":"2015","unstructured":"Ljungberg K, Liljestr\u00f6m P. Self-replicating alphavirus RNA vaccines. Expert Rev Vaccines. 2015;14(2):177\u201394. https:\/\/doi.org\/10.1586\/14760584.2015.965690.","journal-title":"Expert Rev Vaccines"},{"issue":"7324","key":"518_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature09555","volume":"468","author":"JE Voss","year":"2010","unstructured":"Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature. 2010;468(7324):709\u201312. https:\/\/doi.org\/10.1038\/nature09555.","journal-title":"Nature"},{"issue":"6","key":"518_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.83527","volume":"2","author":"P Roques","year":"2017","unstructured":"Roques P, Ljungberg K, K\u00fcmmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight. 2017;2(6):e83527. https:\/\/doi.org\/10.1172\/jci.insight.83527.","journal-title":"JCI Insight"},{"issue":"3","key":"518_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1172\/jci40104","volume":"120","author":"K Labadie","year":"2010","unstructured":"Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest. 2010;120(3):894\u2013906. https:\/\/doi.org\/10.1172\/jci40104.","journal-title":"J Clin Invest"},{"key":"518_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf232","author":"V Legros","year":"2025","unstructured":"Legros V, Belarbi E, Jeannin P, Geolier V, K\u00fcmmerer BM, Hardy D, et al. Use of recombinant Chikungunya virus expressing nanoluciferase to identify chondrocytes as target cells in an immunocompetent mouse model. J Infect Dis. 2025. https:\/\/doi.org\/10.1093\/infdis\/jiaf232.","journal-title":"J Infect Dis"},{"issue":"4","key":"518_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1086\/600381","volume":"200","author":"T Couderc","year":"2009","unstructured":"Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200(4):516\u201323. https:\/\/doi.org\/10.1086\/600381.","journal-title":"J Infect Dis"},{"issue":"3","key":"518_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nm.2105","volume":"16","author":"W Akahata","year":"2010","unstructured":"Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334\u20138. https:\/\/doi.org\/10.1038\/nm.2105.","journal-title":"Nat Med"},{"key":"518_CR14","doi-asserted-by":"publisher","unstructured":"D\u00edaz-Men\u00e9ndez M, Esteban ET, Ujiie M, Calleri G, Rothe C, Malvy D, et al. Travel-associated chikungunya acquired in Myanmar in 2019. Euro Surveill. 2020;25(1). https:\/\/doi.org\/10.2807\/1560-7917.es.2020.25.1.1900721.","DOI":"10.2807\/1560-7917.es.2020.25.1.1900721"},{"key":"518_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102543","volume":"52","author":"AB Mayer","year":"2023","unstructured":"Mayer AB, Consigny PH, Grobusch MP, Camprub\u00ed-Ferrer D, Huits R, Rothe C. Chikungunya in returning travellers from Bali - A GeoSentinel case series. Travel Med Infect Dis. 2023;52:102543. https:\/\/doi.org\/10.1016\/j.tmaid.2023.102543.","journal-title":"Travel Med Infect Dis"},{"key":"518_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2017.03.006","volume":"58","author":"B Wahid","year":"2017","unstructured":"Wahid B, Ali A, Rafique S, Idrees M. Global expansion of Chikungunya virus: mapping the 64-year history. Int J Infect Dis. 2017;58:69\u201376. https:\/\/doi.org\/10.1016\/j.ijid.2017.03.006.","journal-title":"Int J Infect Dis"},{"key":"518_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102603","volume":"54","author":"JD Grabenstein","year":"2023","unstructured":"Grabenstein JD, Tomar AS. Global geotemporal distribution of chikungunya disease, 2011\u20132022. Travel Med Infect Dis. 2023;54:102603. https:\/\/doi.org\/10.1016\/j.tmaid.2023.102603.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"518_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13071-020-3939-0","volume":"13","author":"T Dallimore","year":"2020","unstructured":"Dallimore T, Goodson D, Batke S, Strode C. A potential global surveillance tool for effective, low-cost sampling of invasive Aedes mosquito eggs from tyres using adhesive tape. Parasit Vectors. 2020;13(1):91. https:\/\/doi.org\/10.1186\/s13071-020-3939-0.","journal-title":"Parasit Vectors"},{"issue":"2","key":"518_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s44197-023-00098-0","volume":"13","author":"HI Alguridi","year":"2023","unstructured":"Alguridi HI, Alzahrani F, Altayb HN, Almalki S, Zaki E, Algarni S, et al. The first genomic characterization of the chikungunya virus in Saudi Arabia. J Epidemiol Glob Health. 2023;13(2):191\u20139. https:\/\/doi.org\/10.1007\/s44197-023-00098-0.","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"518_CR20","first-page":"105","volume":"16","author":"B Meason","year":"2014","unstructured":"Meason B, Paterson R. Chikungunya, climate change, and human rights. Health Hum Rights. 2014;16(1):105\u201312.","journal-title":"Health Hum Rights"},{"issue":"3","key":"518_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1172\/jci84417","volume":"127","author":"LA Silva","year":"2017","unstructured":"Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737\u201349. https:\/\/doi.org\/10.1172\/jci84417.","journal-title":"J Clin Invest"},{"key":"518_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102168","volume":"44","author":"R Kumar","year":"2021","unstructured":"Kumar R, Ahmed S, Parray HA, Das S. Chikungunya and arthritis: an overview. Travel Med Infect Dis. 2021;44:102168. https:\/\/doi.org\/10.1016\/j.tmaid.2021.102168.","journal-title":"Travel Med Infect Dis"},{"issue":"7","key":"518_CR23","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cmi.2015.02.024","volume":"21","author":"C Marimoutou","year":"2015","unstructured":"Marimoutou C, Ferraro J, Javelle E, Deparis X, Simon F. Chikungunya infection: self-reported rheumatic morbidity and impaired quality of life persist 6 years later. Clin Microbiol Infect. 2015;21(7):688\u201393. https:\/\/doi.org\/10.1016\/j.cmi.2015.02.024.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"518_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1017\/s0950268810002542","volume":"139","author":"SP Manimunda","year":"2011","unstructured":"Manimunda SP, Mavalankar D, Bandyopadhyay T, Sugunan AP. Chikungunya epidemic-related mortality. Epidemiol Infect. 2011;139(9):1410\u20132. https:\/\/doi.org\/10.1017\/s0950268810002542.","journal-title":"Epidemiol Infect"},{"issue":"suppl 5","key":"518_CR25","doi-asserted-by":"publisher","first-page":"S471","DOI":"10.1093\/infdis\/jiw274","volume":"214","author":"BW Johnson","year":"2016","unstructured":"Johnson BW, Russell BJ, Goodman CH. Laboratory diagnosis of Chikungunya virus infections and commercial sources for diagnostic assays. J Infect Dis. 2016;214(suppl 5):S471\u20134. https:\/\/doi.org\/10.1093\/infdis\/jiw274.","journal-title":"J Infect Dis"},{"issue":"12","key":"518_CR26","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27(12):2224\u201333. https:\/\/doi.org\/10.1038\/s41591-021-01573-6.","journal-title":"Nat Med"},{"issue":"10","key":"518_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/s1473-3099(20)30238-3","volume":"20","author":"N Wressnigg","year":"2020","unstructured":"Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, B\u00e9zay N, Klingler A, et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis. 2020;20(10):1193\u2013203. https:\/\/doi.org\/10.1016\/s1473-3099(20)30238-3.","journal-title":"Lancet Infect Dis"},{"issue":"9959","key":"518_CR28","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/s0140-6736(14)61185-5","volume":"384","author":"LJ Chang","year":"2014","unstructured":"Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014;384(9959):2046\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(14)61185-5.","journal-title":"Lancet"},{"issue":"1","key":"518_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010069","volume":"16","author":"AA Bettis","year":"2022","unstructured":"Bettis AA, L\u2019Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The global epidemiology of chikungunya from 1999 to 2020: a systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis. 2022;16(1):e0010069. https:\/\/doi.org\/10.1371\/journal.pntd.0010069.","journal-title":"PLoS Negl Trop Dis"},{"issue":"10394","key":"518_CR30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/s0140-6736(23)00641-4","volume":"401","author":"M Schneider","year":"2023","unstructured":"Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138\u201347. https:\/\/doi.org\/10.1016\/s0140-6736(23)00641-4.","journal-title":"Lancet"},{"issue":"12","key":"518_CR31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/s1473-3099(24)00357-8","volume":"24","author":"R McMahon","year":"2024","unstructured":"McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infect Dis. 2024;24(12):1383\u201392. https:\/\/doi.org\/10.1016\/s1473-3099(24)00357-8.","journal-title":"Lancet Infect Dis"},{"key":"518_CR32","unstructured":"Release FN. FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus. Accessed 28 June 2025."},{"key":"518_CR33","unstructured":"Agency EM. First vaccine to protect adults from Chikungunya. https:\/\/www.ema.europa.eu\/en\/news\/first-vaccine-protect-adults-chikungunya#:~:text=EMA%20has%20recommended%20granting%20a,given%20as%20a%20single%20dose. Accessed 28 June 2025."},{"key":"518_CR34","unstructured":"Government of Canada DaHPP. Regulatory Decision Summary for Ixchiq. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS1719926004455. Accessed 28 June 2025."},{"key":"518_CR35","unstructured":"FDA. FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-and-cdc-recommend-pause-use-ixchiq-chikungunya-vaccine-live-individuals-60-years-age-and-older?mc_cid=c5fdaad2f0&mc_eid=d74527d6cb. Accessed 21 June 2025."},{"issue":"14","key":"518_CR36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jama.2020.2477","volume":"323","author":"GL Chen","year":"2020","unstructured":"Chen GL, Coates EE, Plummer SH, Carter CA, Berkowitz N, Conan-Cibotti M, et al. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. JAMA. 2020;323(14):1369\u201377. https:\/\/doi.org\/10.1001\/jama.2020.2477.","journal-title":"JAMA"},{"issue":"9","key":"518_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/s1473-3099(22)00226-2","volume":"22","author":"SR Bennett","year":"2022","unstructured":"Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022;22(9):1343\u201355. https:\/\/doi.org\/10.1016\/s1473-3099(22)00226-2.","journal-title":"Lancet Infect Dis"},{"key":"518_CR38","doi-asserted-by":"publisher","unstructured":"Raju S, Adams LJ, Earnest JT, Warfield K, Vang L, Crowe JE Jr., et al. A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci Transl Med. 2023;15(696):eade8273. https:\/\/doi.org\/10.1126\/scitranslmed.ade8273.","DOI":"10.1126\/scitranslmed.ade8273"},{"issue":"10487","key":"518_CR39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/s0140-6736(25)00345-9","volume":"405","author":"JS Richardson","year":"2025","unstructured":"Richardson JS, Anderson DM, Mendy J, Tindale LC, Muhammad S, Loreth T, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10487):1343\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(25)00345-9.","journal-title":"Lancet"},{"key":"518_CR40","unstructured":"FDA. VIMKUNYA. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vimkunya. Accessed 28 June 2025."},{"key":"518_CR41","unstructured":"Agency EM, Vimkunya. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vimkunya. Accessed 28 June 2025."},{"key":"518_CR42","unstructured":"GOV.UK. Vimkunya vaccine approved to prevent disease caused by the chikungunya virus in people 12 years of age and older. https:\/\/www.gov.uk\/government\/news\/vimkunya-vaccine-approved-to-prevent-disease-caused-by-the-chikungunya-virus-in-people-12-years-of-age-and-older. Accessed 28 June 2025."},{"key":"518_CR43","unstructured":"Organization WH, serve on the SAGE Working Group on Chikungunya Vaccines. Call for nomination of experts to. https:\/\/www.who.int\/news-room\/articles-detail\/call-for-nomination-of-experts-sage-working-group-chikungunya-vaccines. Accessed 28 June 2025."},{"key":"518_CR44","unstructured":"CDC. Chikungunya Vaccine Information for Healthcare Providers. https:\/\/www.cdc.gov\/chikungunya\/hcp\/vaccines\/index.html. Accessed 28 June 2025."},{"issue":"6","key":"518_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40259-024-00677-y","volume":"38","author":"WC Weber","year":"2024","unstructured":"Weber WC, Streblow DN, Coffey LL. Chikungunya virus vaccines: a review of IXCHIQ and PXVX0317 from pre-clinical evaluation to licensure. BioDrugs. 2024;38(6):727\u201342. https:\/\/doi.org\/10.1007\/s40259-024-00677-y.","journal-title":"BioDrugs"}],"container-title":["Journal of Epidemiology and Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44197-026-00518-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44197-026-00518-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44197-026-00518-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:06:14Z","timestamp":1772636774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44197-026-00518-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1007\/s44197-026-00518-x","relation":{},"ISSN":["2210-6014"],"issn-type":[{"value":"2210-6014","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"24"}}